Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that its management team will attend the following key investor conferences in the coming months:

  • C. Wainwright 22ndAnnual Global Investment Conference

September 14-16, 2020 (virtual conference)

Onxeo’s management team will present the Company on September 15 at 1:00 pm EDT (19:00 Paris time) and meet with international investors at this conference organized by the American investment bank H. C. Wainwright & Co. This presentation will be available in replay for 90 days on this link.

For more information and to register, click here

  • HealthTech Innovation Days – France Biotech

October 5-6, 2020 in Paris, France (virtual conference)

This event includes conferences and meetings between innovative European companies in the biotechnology, medical technology and digital health sectors, pharmaceutical companies, life science investors as well as experts and opinion leaders in the field of healthcare.

For more information and to register, click here

  • CIC Market Solutions Forum

November 10, 2020 in Paris, France

This event gives the opportunity to French and international investors to interact with executives of listed companies.

For more information and to register, click here

  • Bryan Garnier & Co. European Healthcare Conference

November 16-17, 2020 in Paris, France

This event brings together industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

For more information and to register, click here

  • Direct Dirigeants event – EasyBourse

November 24, 2020 in Paris, France

Presentation by Judith Greciet, CEO of Onxeo, to individual investors and shareholders, moderated by a fund manager.

*    Given the evolving epidemic context, the reader is invited to refer to the organizers’ websites for possible updates to the conditions of participation.